In February and March, I wrote about Sesen Bio’s (SESN) vast potential. Dr. Thomas Cannell, President & CEO, conducted a conference call on May 13 that presented information pretty much as I anticipated: directionally, timewise & strategically.
Brief Background
In our world of unrealistic expectations and instant gratification, it is easy to understand how many would deride a drug that achieved a scant 15% Complete Response Rate ((CRR)) at 12 months. Bladder cancer is the 4thmost prevalent cancer among men in the U.S.; 80% of patients are diagnosed with